Browsing NTNU Open by Author "Haavardsholm, Espen A."
Now showing items 1-8 of 8
-
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial
Hetland, Merete Lund; Haavardsholm, Espen A.; Rudin, Anna; Nordström, Dan C.; Nurmohamed, Michael; Gudbjornsson, Bjorn; Lampa, Jon; Hørslev-Petersen, Kim; Uhlig, Till; Grondal, Gerdur; Østergaard, Mikkel; Schrumpf, Marte; Twisk, Jos; Lend, Kristina; Krabbe, Simon; Hyldstrup, Lise; Lindqvist, Joakim; Hultgård Ekwall, Anna-Karin; Grøn, Kathrine Lederballe; Kapetanovic, Meliha C.; Faustini, Francesca; Tuompo, Riitta; Lorenzen, Tove; Cagnotto, Giovanni; Baecklund, Eva; Hendricks, Oliver; Vedder, Daisy; Sokka-Isler, Tuulikki; Husmark, Tomas; Ljoså, Maud-Kristine Aga; Brodin, Eli; Ellingsen, Torkell; Söderbergh, Annika; Rizk, Milad; Olsson, Åsa Reckner; Larsson, Per; Uhrenholt, Line; Just, Søren Andreas; Stevens, David John; Laurberg, Trine Bay; Bakland, Gunnstein; Olsen, Inge Christoffer; Vollenhoven, Ronald F. (Peer reviewed; Journal article, 2020)Objective To evaluate and compare benefits and harms of three biological treatments with different modes of action versus active conventional treatment in patients with early rheumatoid arthritis. Design Investigator ... -
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
Østergaard, Mikkel; Van Vollenhoven, Ronald F; Rudin, Anna; Hetland, Merete Lund; Schrumpf, Marte; Nordström, Dan C; Nurmohamed, Michael T; Gudbjornsson, Bjorn; Ørnbjerg, Lykke Midtbøll; Bøyesen, Pernille; Lend, Kristina; Hørslev-Petersen, Kim; Uhlig, Till; Sokka, Tuulikki; Grondal, Gerdur; Krabbe, Simon; Lindqvist, Joakim; Gjertsson, Inger; Glinatsi, Daniel; Kapetanovic, Meliha Crnkic; Aga, Anna-Birgitte; Faustini, Francesca; Parmanne, Pinja; Lorenzen, Tove; Giovanni, Cagnotto; Back, Johan; Hendricks, Oliver; Vedder, Daisy; Rannio, Tuomas; Grenholm, Emma; Ljoså, Maud-Kristine Aga; Brodin, Eli; Lindegaard, Hanne; Söderbergh, Annika; Rizk, Milad; Kastbom, Alf; Larsson, Per; Uhrenholt, Line; Just, Søren Andreas; Stevens, David John; Bay Laurbjerg, Trine; Bakland, Gunnstein; Olsen, Inge Christoffer; Haavardsholm, Espen A.; Lampa, Jon (Peer reviewed; Journal article, 2023)Background - The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic outcomes of active conventional therapy with each of three biological treatments with ... -
The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial
Gjefsen, Elisabeth; Bråten, Lars Christian Haugli; Goll, Guro Løvik; Wigemyr, Monica; Bolstad, Nils; Valberg, Morten; Schistad, Ellina Iordanova; Marchand, Gunn Hege; Granviken, Fredrik; Selmer, Kaja Kristine; Johanessen, Anne Froholdt; Haugen, Anne Julsrud; Dagestad, Magnhild Hammersland; Vetti, Nils; Bakland, Gunnstein; Lie, Benedicte Alexandra; Haavardsholm, Espen A.; Nilsen, Aksel Thuv; Holmgard, Thor Einar; Kadar, Thomas; Kvien, Tore Kristian; Skouen, Jan Sture; Grøvle, Lars; Brox, Jens Ivar; Espeland, Ansgar; Storheim, Kjersti; Zwart, John-Anker (Peer reviewed; Journal article, 2020)Low back pain is common and a significant number of patients experience chronic low back pain. Current treatment options offer small to moderate effects. Patients with vertebral bone marrow lesions visualized as Modic ... -
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Syversen, Silje Watterdal; Goll, Guro Løvik; Jørgensen, Kristin Kaasen; Sandanger, Øystein; Sexton, Joseph; Olsen, Inge Christoffer; Gehin, Johanna Elin; Warren, David; Brun, Marthe Kirkesæther; Klaasen, Rolf; Karlsen, Lars Normann; Noraberg, Geir; Zettel, Camilla; Ljoså, Maud-Kristine Aga; Haugen, Anne Julsrud; Njålla, Rune Johan; Bruun, Trude J; Seeberg, Kathrine; Michelsen, Brigitte; Strand, Eldri Kveine; Skorpe, Svanaug; Blomgren, Ingrid; Bragnes, Yngvill; Dotterud, Christian; Thune, Turid Jorunn; Ystrøm, Carl Magnus; Torp, Roald; Pawel, Mielnik; Mørk, Cato; Kvien, Tore Kristian; Jahnsen, Jørgen; Bolstad, Nils; Haavardsholm, Espen A. (Peer reviewed; Journal article, 2021)Importance: Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy ... -
Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs
Brkic, Alen; Diamantopoulos, Andreas P; Haavardsholm, Espen A.; Fevang, Bjørg Tilde Svanes; Brekke, Lene Kristin; Loli, Liz Paucar; Zettel, Camilla; Rødevand, Erik; Bakland, Gunnstein; Pawel, Mielnik; Haugeberg, Glenn (Peer reviewed; Journal article, 2022)Background In Norway, an annual tender system for the prescription of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) has been used since 2007. This study aimed to explore annual ... -
Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010–2019)
Brkic, Alen; Diamantopoulos, Andreas P; Hoff, Mari; Haavardsholm, Espen A.; Fevang, Bjørg Tilde Svanes; Brekke, Lene Kristin; Loli, Liz Paucar; Zettel, Camilla; Bakland, Gunnstein; Pawel, Mielnik; Haugeberg, Glenn (Peer reviewed; Journal article, 2023)Background Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) are highly effective in treating rheumatoid arthritis (RA), albeit high drug cost has restricted their use in many countries. ... -
Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial
Goll, Guro Løvik; Jørgensen, Kristin Kaasen; Sexton, Joseph; Olsen, Inge Christoffer; Bolstad, Nils; Haavardsholm, Espen A.; Lundin, Knut Erik Aslaksen; Tveit, Kåre Steinar; Lorentzen, Merete; Berset, Ingrid Prytz; Fevang, Bjørg-Tilde Svanes; Kalstad, Synnøve; Ryggen, Kristin; Warren, David; Klaasen, Rolf; Asak, Øivind Wessel; Baigh, Somyeh; Blomgren, Ingrid; Brenna, Øystein; Bruun, Trude J; Dvergsnes, Katrine; Frigstad, Svein Oskar; Myrnes, Inger; Hatten, Ingvild Helgheim; Huppertz-Hauss, Gert; Henriksen, Magne; Hoie, Sunniva S.; Krogh, Jan Reidar; Midtgard, Irina P.; Mielnik, Pawel; Moum, Bjørn; Noraberg, Geir; Poyan, Armin; Prestegård, Ulf; Rashid, Haroon Ur; Strand, Eldri Kveine; Skjetne, Kristine; Seeberg, Kathrine; Torp, Roald; Ystrøm, Carl Magnus; Vold, Cecilia; Zettel, Camilla C.; Waksvik, Kenneth; Gulbrandsen, Bjørn; Hagfors, Jon; Mørk, Cato; Jahnsen, Jørgen; Kvien, Tore Kristian (Journal article; Peer reviewed, 2019)Background and objectives The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not ... -
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Jørgensen, Kristin Kaasen; Inge Christoffer, Olsen; Goll, Guro Løvik; Lorentzen, Merete; Bolstad, Nils; Haavardsholm, Espen A.; Lundin, Knut Erik Aslaksen; Mørk, Cato; Jahnsen, Jørgen; Kvien, Tore Kristian (Journal article; Peer reviewed, 2017)Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but are expensive therapies. The aim ...